SOLIGENIX INC (SNGX) Stock Price, Quote, News and Overview
NASDAQ:SNGX - Nasdaq - US8342236044 - Common Stock - Currency: USD
SNGX Quote, Performance and Key Statistics
2.43
-0.01 (-0.41%)
The current stock price of SNGX is 2.43 USD. In the past month the price decreased by -3.19%. In the past year, price decreased by -80.2%.
SNGX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About SNGX
Company Profile
Soligenix Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Princeton, New Jersey and currently employs 13 full-time employees. Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics segment is developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Development programs in this segment also include expansion of synthetic hypericin (SGX302) into psoriasis and dusquetide (SGX942 and SGX945) for the treatment of inflammatory diseases. Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19.
Company Info
SOLIGENIX INC
29 Emmons Drive, Suite B-10
Princeton NEW JERSEY 08540 US
CEO: Christopher J. Schaber
Employees: 14
Company Website: https://www.soligenix.com/
Investor Relations: http://ir.soligenix.com
Phone: 16095388200
SOLIGENIX INC / SNGX FAQ
What is the stock price of SOLIGENIX INC today?
The current stock price of SNGX is 2.43 USD. The price decreased by -0.41% in the last trading session.
What is the ticker symbol for SOLIGENIX INC stock?
The exchange symbol of SOLIGENIX INC is SNGX and it is listed on the Nasdaq exchange.
On which exchange is SNGX stock listed?
SNGX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SOLIGENIX INC stock?
7 analysts have analysed SNGX and the average price target is 22.95 USD. This implies a price increase of 844.44% is expected in the next year compared to the current price of 2.43. Check the SOLIGENIX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SOLIGENIX INC worth?
SOLIGENIX INC (SNGX) has a market capitalization of 6.10M USD. This makes SNGX a Nano Cap stock.
How many employees does SOLIGENIX INC have?
SOLIGENIX INC (SNGX) currently has 14 employees.
What are the support and resistance levels for SOLIGENIX INC (SNGX) stock?
SOLIGENIX INC (SNGX) has a support level at 2.42 and a resistance level at 2.44. Check the full technical report for a detailed analysis of SNGX support and resistance levels.
Is SOLIGENIX INC (SNGX) expected to grow?
The Revenue of SOLIGENIX INC (SNGX) is expected to decline by -36.11% in the next year. Check the estimates tab for more information on the SNGX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SOLIGENIX INC (SNGX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SNGX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SNGX, evaluating the profitability, health, valuation and growth aspects
- SOLIGENIX INC (SNGX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SOLIGENIX INC (SNGX) Sales and EPS estimates to see what analysts future expectations are.
- SOLIGENIX INC (SNGX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SOLIGENIX INC (SNGX) Insider and Institutional Ownership to learn about the owners and their transactions.
- SOLIGENIX INC (SNGX) Stock Chart to make your own analysis
- SOLIGENIX INC (SNGX) Latest news and press-releases to stay up to date.
Does SOLIGENIX INC (SNGX) stock pay dividends?
SNGX does not pay a dividend.
When does SOLIGENIX INC (SNGX) report earnings?
SOLIGENIX INC (SNGX) will report earnings on 2025-03-13, after the market close.
What is the Price/Earnings (PE) ratio of SOLIGENIX INC (SNGX)?
SOLIGENIX INC (SNGX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-8.65).
What is the Short Interest ratio of SOLIGENIX INC (SNGX) stock?
The outstanding short interest for SOLIGENIX INC (SNGX) is 4.82% of its float. Check the ownership tab for more information on the SNGX short interest.
SNGX Technical Analysis
SNGX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SNGX. SNGX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
SNGX Financial Highlights
Over the last trailing twelve months SNGX reported a non-GAAP Earnings per Share(EPS) of -8.65. The EPS increased by 89.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -67.76% | ||
| ROE | -119.61% | ||
| Debt/Equity | 0 |
SNGX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to SNGX. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 62.08% and a revenue growth -36.11% for SNGX